Displaying drugs 5226 - 5250 of 11493 in total
7beta-hydroxycholesterol
Experimental
Matched Iupac: … 11a-dimethyl-1-[(2R)-6-methylheptan-2-yl]-1H,2H,3H,3aH,3bH,4H,6H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a] …
Fluprednidene
Fluprednidene is a corticosteroid.
Experimental
Matched Iupac: … hydroxyacetyl)-9a,11a-dimethyl-2-methylidene-1H,2H,3H,3aH,3bH,4H,5H,7H,9aH,9bH,10H,11H,11aH-cyclopenta[a] …
Matched Description: … Fluprednidene is a corticosteroid. …
Matched Description: … Fluprednidene is a corticosteroid. …
AI-850
AI-850 is a Cremophor(R)-free formulation of paclitaxel, the active ingredient in Taxol(R), a product used to treat a variety of solid tumors.
Investigational
Matched Description: … AI-850 is a Cremophor(R)-free formulation of paclitaxel, the active ingredient in Taxol(R), a product ... used to treat a variety of solid tumors. …
AV-412
Investigational
AT-527
Investigational
AL-034
AL-034 (TQ-A3334) is an oral toll-like receptor 7 agonist developed for the treatment of chronic hepatitis B (CHB) viral infection.
Investigational
AGF-94
Investigational
AP-102
Investigational
AL-4623
Experimental
ABT-510
ABT-510 is a peptide mimetic of thrombospondin-1 (TSP-1), blocks angiogenesis in vitro and in vivo, and slows tumor growth. It is developed by Abbott Laboratories for the treatment of Solid Tumors, Lymphoma and Melanoma.
Investigational
Matched Description: … ABT-510 is a peptide mimetic of thrombospondin-1 (TSP-1), blocks angiogenesis in vitro and in vivo, and …
AMG-131
AMG-131 (T131), an orally-administered therapy, is expected to lower blood glucose in type II diabetic patients by improving the body’s ability to respond to insulin. T131 is a selective modulator of PPARg (peroxisome proliferator activated receptor gamma), a receptor involved in regulating the body’s ability to respond to insulin. T131...
Investigational
Matched Description: … T131 is a selective modulator of PPARg (peroxisome proliferator activated receptor gamma), a receptor …
AGS-004
AGS-004 is a personalized RNA-loaded dendritic cellbased
immunotherapy that is designed to stimulate the patient’s immune system to target and destroy the patient’s own unique viral burden. Non-personalized HIV immunotherapies are unable to raise cytotoxic T lymphocytes against HIV antigens, fail to induce T cell memory, and, most importantly, do...
Investigational
Matched Description: … , providing a matched, complete immune response for each individual HIV patient. ... AGS-004 is a personalized RNA-loaded dendritic cellbased
immunotherapy that is designed to stimulate ... This approach may overcome the weaknesses of other available therapies and therefore could result in a …
ATX-201
ATX-201 is one of a family of novel compounds that inhibits microtubule polymerization. It is developed by Kythera Biopharmaceuticals, Inc. for the treatment of actinic
keratosis. The company announced the decision to discontinue its ATX-201 clinical program for actinic keratosis. The Company determined that the program was not meeting their...
Investigational
Matched Description: … ATX-201 is one of a family of novel compounds that inhibits microtubule polymerization. …
ANZ-100
Investigational
AIT-034
AIT-034 is a distinct chemical analog of hypoxanthine and pyrollidone that has been demonstrated in animal studies to enhance memory and to reverse memory deficits in severely impaired animals that do not respond to Neotrofin. AIT-034 does not induce the production of NGF, and its mechanism of action is therefore...
Investigational
Matched Description: … AIT-034 is a distinct chemical analog of hypoxanthine and pyrollidone that has been demonstrated in animal ... There is some evidence that AIT-034 could complement Neotrofin as a treatment for Alzheimer's disease …
AS-8112
AS-8112 is a synthetic compound that acts as a selective antagonist at the dopamine receptor subtypes D2 and D3, and the serotonin receptor 5-HT3. It has been shown to exert potent antiemetic effects in animal studies and has been investigated for potential medical use.
Experimental
Matched Description: … AS-8112 is a synthetic compound that acts as a selective antagonist at the dopamine receptor subtypes …
AKN-028
AKN-028 has been used in trials studying the treatment of Acute Myeloid Leukemia.
Investigational
Apomab
Apomab is under investigation in clinical trial NCT00851136 (A Study of PRO95780 Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, and Metastatic Colorectal Cancer (APM4566g)).
Investigational
Matched Description: … Apomab is under investigation in clinical trial NCT00851136 (A Study of PRO95780 Administered in Combination …
Avidin
Avidin is under investigation in clinical trial NCT00345618 (Clinical Study Assessing Idrabiotaparinux Sodium Injections Once-weekly in Pulmonary Embolism Therapeutic Approach).
Investigational
AGG-523
AGG-523 is under investigation in clinical trial NCT00380900 (Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses in Healthy subjects and in subjects with osteoarthritis).
Investigational
AUNP-12
Investigational
ABX-196
ABX-196 is under investigation in clinical trial NCT03897543 (ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma).
Investigational
AGIL-FA
Investigational
Displaying drugs 5226 - 5250 of 11493 in total